Author + information
- Nathan D. Wong,
- Wenjun Fan,
- Sephy Philip,
- Craig Granowitz and
- Peter Toth
Persons with hypertriglyceridemia (HTG) have greater risks for atherosclerotic cardiovascular disease (ASCVD), and statin therapy is indicated as initial treatment. Our aim was to estimate ASCVD risk and events for persons with and without HTG, according to statin use.
We studied 4,986 adults (projected to 113 million) aged 40-79 without ASCVD from the US National Health and Nutrition Examination Survey 2007-2014 classified by fasting triglycerides (TG): <150, 150-199, 200-499, and >500 mg/dL and statin use. We used the ACC/AHA risk calculator to estimate 10-year risk of ASCVD. ASCVD events (in millions, M) expected to occur over 10 years were calculated by multiplying the estimated ASCVD risk with corresponding projected population sizes.
The table shows the mean estimated 10-year risk of ASCVD events by statin use within TG groups. 29% of subjects had TG of >150 mg/dL. Mean overall 10-year ASCVD risk ranged from 7.1% with TG <150 mg/dL to 16.1% with TG ≥500 mg/dL. 9.1M ASCVD events overall were projected to occur over the next 10-years; 37% or 3.4M were projected to occur in those with TG of 150 mg/dL or higher. Of these, 1.14 million (34%) were projected to occur in statin users.
Over one-third of projected ASCVD events (3.4M) occur in persons with TG of >150 mg/dL, including 1.14M events among statin users. There is urgent need to address this under-recognized excess risk and examine the capacity of lifestyle modification and other therapies to attenuate ASCVD risk.
Poster Hall, Hall F
Saturday, March 16, 2019, 3:45 p.m.-4:30 p.m.
Session Title: Prevention: Clinical 2
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1178-417
- 2019 American College of Cardiology Foundation